Trial Profile
Occurrence of Anti-drug Antibody and Change of Drug Level for 1 Year After CT-P13 Therapy and Their Impact on Clinical Outcomes in Moderate to Severe Inflammatory Bowel Disease (OACIS Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms OACIS
- 15 Feb 2021 Status changed from recruiting to completed.
- 19 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Sep 2018.
- 29 Jul 2016 New trial record